Journal Mobile Options
Table of Contents
Vol. 107, No. 1, 2007
Issue release date: September 2007
Section title: Original Paper
Nephron Clin Pract 2007;107:c26–c34
(DOI:10.1159/000106509)

Antiglycation and Antioxidant Effect of Carnosine against Glucose Degradation Products in Peritoneal Mesothelial Cells

Alhamdani M.-S.S. · Al-Kassir A.-H.A.-M. · Abbas F.K.H. · Jaleel N.A. · Al-Taee M.F.
aDepartment of Medical Sciences, College of Pharmacy, and bDepartment of Internal Medicine, College of Medicine, Al-Mustansiriya University; cArtificial Kidney Unit, Al-Karama Teaching Hospital, dArtificial Kidney Unit, Al-Yarmuk Teaching Hospital, and eBiotechnology Department, College of Sciences, Al-Nahrain University, Baghdad, Iraq

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 1/5/2007
Accepted: 4/24/2007
Published online: 7/31/2007

Number of Print Pages: 1
Number of Figures: 6
Number of Tables: 0

ISSN: (Print)
eISSN: 1660-2110 (Online)

For additional information: http://www.karger.com/NEC

Abstract

Background/Aim:Toxicity with advanced glycation end products (AGEs) is a major problem in uremic patients. Treatment with peritoneal dialysis (PD) exacerbates AGE formation as a result of bioincompatibility of the conventional peritoneal dialysis fluid (PDF). The presence of glucose degradation products (GDPs) in PDF is the main cause of its bioincompatibility. Carnosine is an endogenous dipeptide with a powerful antiglycation/antioxidant activity. In an attempt to improve PDF biocompatibility, we evaluated the effect of carnosine in human peritoneal mesothelial cells (HPMC) incubated with PDF or GDPs in vitro. Methods: HPMC were incubated for short or prolonged time with PDF in the presence or absence of carnosine. Similarly, HPMC were incubated in the same condition but with a combination of GDPs. Following the incubation, cells were tested for their viability, protein carbonyl content and reactive oxygen species (ROS) production. Results: Results demonstrated a significant protective effect of carnosine to HPMC in both acute and chronic conditions with PDF or GDPs as judged by the enhancement of cell viability, preserved protein from modification and decreased ROS production. Conclusion: Carnosine enhanced HPMC viability against the toxic effect of GDPs probably through protection of cellular protein from modification and from ROS-mediated oxidative damage. The salutary effect of carnosine may render it a desirable candidate for improving PDF biocompatibility and reducing AGE complications in PD patients.


  

Author Contacts

Mohamed-Saiel Saeed Alhamdani
Department of Medical Sciences, College of Pharmacy, Al-Mustansiriya University Dora Highway, Baghdad (Iraq)
Tel. +964 7901 652 459 or +964 7702 751 990
E-Mail ms.alhamdani@gmail.com

  

Article Information

Received: January 5, 2007
Accepted: April 24, 2007
Published online: July 31, 2007
Number of Print Pages : 9
Number of Figures : 6, Number of Tables : 0, Number of References : 45

  

Publication Details

Nephron Clinical Practice

Vol. 107, No. 1, Year 2007 (Cover Date: September 2007)

Journal Editor: Powis, S.H. (London)
ISSN: 1660–2110 (print), 1660–2110 (Online)

For additional information: http://www.karger.com/NEC


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 1/5/2007
Accepted: 4/24/2007
Published online: 7/31/2007

Number of Print Pages: 1
Number of Figures: 6
Number of Tables: 0

ISSN: (Print)
eISSN: 1660-2110 (Online)

For additional information: http://www.karger.com/NEC


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.